Literature DB >> 3489745

The role of exercise testing in identifying patients with improved survival after coronary artery bypass surgery.

D A Weiner, T J Ryan, C H McCabe, B R Chaitman, L T Sheffield, L D Fisher, F Tristani.   

Abstract

To determine whether exercise testing can identify patients whose survival might be prolonged by coronary artery bypass surgery, the results of bypass surgery were compared with those of medical therapy alone in 5,303 nonrandomized patients from the Coronary Artery Surgery Study registry who underwent exercise testing. Patients in the two treatment groups differed substantially with regard to important baseline variables. Analysis of 32 variables by Cox's regression model for survival revealed an independent beneficial effect of bypass surgery on survival (p less than 0.00001). Patients were then stratified into subsets according to the results of exercise testing. Surgical benefit was greatest in the 789 patients who exhibited at least 1 mm of ST segment depression and who could exercise only into stage 1 or less. Among the 398 patients with three vessel coronary disease showing these characteristics, 7 year survival was 58% for the medical group and 81% for the surgical group (p less than 0.001). There was no difference in survival between the surgical and medical groups among the 1,545 patients without ischemic ST segment depression who were able to exercise into stage 3 or greater. Thus, in patients who demonstrate ischemia on exercise testing and whose exercise capacity is limited, coronary bypass surgery appears to improve survival in comparison with medical therapy alone.

Entities:  

Mesh:

Year:  1986        PMID: 3489745     DOI: 10.1016/s0735-1097(86)80412-0

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  12 in total

1.  Coronary artery bypass in perspective.

Authors:  R J Hall
Journal:  Tex Heart Inst J       Date:  1989

2.  MDCT is better than stress perfusion imaging for detecting CAD--Against.

Authors:  Marcelo F Di Carli; Rory Hachamovitch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03       Impact factor: 9.236

Review 3.  Integrated cardiac PET-CT for the diagnosis and management of CAD.

Authors:  Marcelo F Di Carli; Sharmila Dorbala; Rory Hachamovitch
Journal:  J Nucl Cardiol       Date:  2006 Mar-Apr       Impact factor: 5.952

4.  Nuclear cardiology will remain the "gatekeeper" over CT angiography.

Authors:  Rory Hachamovitch; Marcelo F Di Carli
Journal:  J Nucl Cardiol       Date:  2007 Sep-Oct       Impact factor: 5.952

5.  Predicting therapeutic benefit from myocardial revascularization procedures: are measurements of both resting left ventricular ejection fraction and stress-induced myocardial ischemia necessary?

Authors:  Rory Hachamovitch; Alan Rozanski; Sean W Hayes; Louise E J Thomson; Guido Germano; John D Friedman; Ishac Cohen; Daniel S Berman
Journal:  J Nucl Cardiol       Date:  2006-11       Impact factor: 5.952

6.  Cardiac PET/CT for the evaluation of known or suspected coronary artery disease.

Authors:  Marcelo F Di Carli; Venkatesh L Murthy
Journal:  Radiographics       Date:  2011 Sep-Oct       Impact factor: 5.333

Review 7.  Stress testing. Directions for the future.

Authors:  C Foster
Journal:  Sports Med       Date:  1988-07       Impact factor: 11.136

8.  Myocardial revascularization. Historical considerations.

Authors:  R J Hall
Journal:  Tex Heart Inst J       Date:  1994

9.  Selecting the best noninvasive imaging test to guide treatment after an inconclusive exercise test.

Authors:  Angela S Koh; Ron Blankstein
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-02

10.  Relationship between CT coronary angiography and stress perfusion imaging in patients with suspected ischemic heart disease assessed by integrated PET-CT imaging.

Authors:  Marcelo F Di Carli; Sharmila Dorbala; Zelmira Curillova; Raymond J Kwong; Samuel Z Goldhaber; Frank J Rybicki; Rory Hachamovitch
Journal:  J Nucl Cardiol       Date:  2007-10-22       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.